Pharmaceutical value under uncertainty: a theory of reproducible therapeutic surplus

Pharmacoeconomics has achieved considerable influence by providing formal tools for comparing pharmaceutical interventions in terms of costs and consequences. Its most established instruments, especially cost-effectiveness analysis and related evaluative frameworks, have supplied health systems with a disciplined language for priority setting, reimbursement appraisal and resource allocation (1,2). This contribution is substantial and should not be understated. Yet the intellectual success of conventional pharmacoeconomics has also encouraged a narrowing of its theoretical horizon. In much of its dominant form, pharmaceutical value is treated as if it could be adequately represented through a relatively static relation between present expenditure and measurable health gain.That reduction has analytical advantages, but it also entails a substantial loss of theoretical depth. Pharmaceutical interventions do not enter empty calculative space. They are introduced into health systems characterised by imperfect information, asymmetries of institutional power, intertemporal trade-offs, administrative delay, evidential incompleteness and politically mediated thresholds of acceptability. Even where the formal apparatus of economic evaluation is technically rigorous, the broader process by which value is formed, recognised and acted upon remains only partially captured by standard efficiency metrics. In this sense, conventional pharmacoeconomics is not wrong so much as incomplete. It explains an important part of the problem, but not the full architecture within which pharmaceutical value is generated and judged. This incompleteness becomes particularly evident once one distinguishes between the evaluation of a medicine as an isolated intervention and the evaluation of a medicine as an element within a reproducing institutional system. A pharmaceutical technology may satisfy conventional criteria of efficiency while simultaneously imposing strains on future therapeutic organisation, reimbursement flexibility, supply resilience or distributive legitimacy. By the same token, a therapy that appears expensive in the short run may contribute to the strengthening of long-term therapeutic capacity by reducing downstream fragility, preserving clinical options or stabilising patterns of care. The prevailing analytical vocabulary of pharmacoeconomics has struggled to articulate these broader dynamics in a systematic way.The reduction of pharmaceutical value to static efficiency is increasingly difficult to defend. Even within mainstream health economics, important work has acknowledged that cost-effectiveness analysis, although indispensable, does not exhaust the evaluative terrain of health policy (3,4). Health technology assessment bodies routinely consider matters that exceed the simple ratio between cost and effect, including severity, uncertainty, unmet need, feasibility of implementation, budgetary sustainability and wider social or institutional concerns. The real decision space is therefore already broader than the formal language by which it is often represented. Moreover, pharmaceutical decision-making unfolds under conditions of uncertainty that are not merely technical but structural. Evidence at the point of pricing and reimbursement is frequently incomplete, immature or contingent upon evolving real-world use. Uncertainty concerns not only parameter values in a model, but the stability of treatment effects over time, the generalisability of trial results, the behaviour of providers and patients, the durability of supply, and the institutional willingness to sustain funding commitments. For this reason, uncertainty is not an external nuisance appended to otherwise stable valuations; it is internal to the constitution of value itself (5)(6)(7).A further limitation of static efficiency lies in its weak grasp of temporality. Static assessment is primarily concerned with whether a given intervention appears worthwhile at the moment of appraisal. Yet pharmaceutical systems are not static allocation devices. They are historically layered, institutionally constrained and continuously reproducing arrangements that must preserve future therapeutic possibility while managing present scarcity. Recent work on dynamic efficiency has this point by that may the conditions to sustain and therapeutic the same It also to the capacity of health systems to preserve therapeutic resilience and value is only as is the of whether present pharmaceutical or the future conditions of care. A health may interventions that are within while in distributive or it may or interventions contribution lies in to therapeutic under Static efficiency is therefore a but It a of but not its full and institutional a theoretical to that Its is that pharmaceutical value should be not only in relation to health and present but also in relation to the capacity of a pharmaceutical intervention to or the future therapeutic of the health system. the the of therapeutic The to the generated a pharmaceutical intervention present therapeutic while also the institutional and conditions under which future therapeutic to be contribution is the a of standard by that its dominant evaluative in the of uncertainty, institutional and intertemporal it an through which pharmaceutical value may be as an institutionally mediated and than as a merely static efficiency This does not economic it to economic evaluation within a of therapeutic value is politically and historically broader of the is to the theoretical of pharmacoeconomics by it into with institutional and of pharmaceutical systems are only by in the the conditions that therapeutic A must therefore not only whether a medicine is but whether it to the of therapeutic capacity under conditions of uncertainty, and institutional It is this that the present analysis has the most analytical language of pharmacoeconomics it a disciplined to therapeutic under resource Its lies in its costs are related to are